-
Media ReleaseNovartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
-
Media ReleaseNovartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
-
Media ReleaseNew Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
-
Media ReleaseNovartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
-
Media ReleaseNovartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
-
Media ReleaseNovartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
-
Media ReleaseNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
-
Media ReleaseAveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
-
Media ReleaseEntresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
-
Media ReleaseNovartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home
-
Media ReleaseFDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
-
Media ReleaseNovartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions